Enhancing radiotherapy with genetically engineered viruses

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4090-4095

  Advani, Sunil J ^a   Weichselbaum, Ralph R ^a   Chmura, Steven J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUCYTOSINE; FLUOROURACIL; G 1716; G 207; GANCICLOVIR; NV 1020; ONCOLYTIC HERPES SIMPLEX VIRUS 1; ONCOLYTIC VIRUS; ONYX 015; THYMIDINE KINASE; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALACICLOVIR;

ADJUVANT THERAPY; BILE DUCT CARCINOMA; CANCER GENE THERAPY; CANCER RADIOTHERAPY; DNA REPLICATION; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; GENETIC ENGINEERING; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; MELANOMA; MESOTHELIOMA; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIOSENSITIZATION; REVIEW; THROMBOEMBOLISM; TUMOR GROWTH; UTERINE CERVIX CANCER; VIRUS REPLICATION; GENE THERAPY; GENETICS; METHODOLOGY; NEOPLASM; VIRUS;

GENE THERAPY; HUMANS; NEOPLASMS; VIRUSES;

EID: 34748820026     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.2739     Document Type: Review

References (52)

1. Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82:297-300, 1990
2. Ezzeddine ZD, Martuza RL, Platika D, et al: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 3:608-614, 1991
3. Niranjan A, Moriuchi S, Lunsford LD, et al: Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2:114-120, 2000
4. Moriuchi S, Krisky DM, Marconi PC, et al: HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther 7:1483-1490, 2000
5. Kim JH, Kim SH, Kolozsvary A, et al: Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 33:861-868, 1995
6. Kim JH, Kim SH, Brown SL, et al: Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 54:6053-6056, 1994
7. Teh BS, Ayala G, Aguilar L, et al: Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58:1520-1529, 2004
8. Stackhouse MA, Pederson LC, Grizzle WE, et al: Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther 7:1019-1026, 2000
9. Pederson LC, Buchsbaum DJ, Vickers SM, et al: Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 57:4325-4332, 1997
10. Rogulski KR, Zhang K, Kolozsvary A, et al: Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 3:2081-2088, 1997
11. Freytag SO, Strieker H, Pegg J, et al: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformai radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63:7497-7506, 2003
12. Kun LE, Gajjar A, Muhlbauer M, et al: Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa. 7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 6:1231-1255, 1995
13. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401, 2000
14. Schwarzenberger P, Harrison L, Weinacker A, et al: The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study. Hum Gene Ther 9:2641-2649, 1998
15. Schwarzenberger P, Harrison L, Weinacker A, et al: Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 150:168-174, 1998
16. Eck SL, Alavi JB, Alavi A, et al: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial. Hum Gene Ther 7:1465-1482, 1996
17. Klatzmann D, Valery CA, Bensimon G, et al: A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma: Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9:2595-2604, 1998
18. Klatzmann D, Cherin P, Bensimon G, et al: A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma: Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 9:2585-2594, 1998
19. Ram Z, Culver KW, Oshiro EM, et al: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361, 1997
20. Sherman ML, Datta R, Hallahan DE, et al: Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci U S A 87:5663-5666, 1990
21. Hallahan DE, Virudachalam S, Beckett M, et al: Mechanisms of X-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines. Int J Radiat Oncol Biol Phys 21: 1677-1681, 1991
22. Hallahan DE, Sukhatme VP, Sherman ML, et al: Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci U S A 88:2156-2160, 1991
23. Datta R, Rubin E, Sukhatme V, et al: Ionizing radiation activates transcription of the EGRI gene via CArG elements. Proc Natl Acad Sci U S A 89:10149-10153, 1992
24. Datta R, Taneja N, Sukhatme VP, et al: Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A 90:2419-2422, 1993
25. Old LJ: Tumor necrosis factor (TNF). Science 230:630-632, 1985
26. Hallahan DE, Vokes EE, Rubin SJ, et al: Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am 1:204-209, 1995
27. Hallahan DE, Mauceri HJ, Seung LP, et al: Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1:786-791, 1995
28. Mauceri HJ, Seung LP, Grdina WL, et al: Increased injection number enhances adenoviral genetic radiotherapy. Radiat Oncol Investig 5:220-226, 1997
29. Staba MJ, Mauceri HJ, Kufe DW, et al: Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 5:293-300, 1998
30. Chung TD, Mauceri HJ, Hallahan DE, et al: Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther 5:344-349, 1998
31. Sharma A, Mani S, Hanna N, et al: Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther 12:1109-1131, 2001
32. Sharma AKH, Nemunaitis J, Posner M, et al: Phase I dose escalation study of tumor necrosis factor-alpha. Gene transfer with radiation therapy for advanced solid tumors. Proc Am Soc Ther Radiat Oncol, 2001 (abstr 187)
33. Hanna NN, Nemunaitis J, Cunningham CC, et al: A phase I study of human necrosis factor-alpha gene transfer with radiation therapy for advanced solid tumors. Proc Am Soc Clin Oncol 21:87a, 2002 (abstr 344)
34. Senzer N, Chung T, Hecht JR, et al: Safety and efficacy of TNFerade in unresectable, locally advanced pancreatic cancer)LAPC): Results of the first three cohorts of a dose-escalating study. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA
35. Senzer N, Reid T, Mauer A, et al: Long-term outcome in esophageal cancer after endoscopically delivered intratumoral (IT) injections of TNFerade with neoadjuvant chemoradiotherapy (CRT), 2006. Presented at the Gastrointestinal Cancers Symposium, January 26-28, 2006, San Francisco, CA
36. Senzer N, Javle M, Reid T, et al: The PACT trial: Interim results of a randomized trial of TNFerade biologic plus chemoradiation (CRT) compared to CRT alone in locally advanced pancreatic cancer (LAPC). J Clin Oncol 24:203s, 2006 (suppl; abstr 4102)
37. Martuza RL, Malick A, Marken JM, et al: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991
38. Chou J, Kern ER, Whitley RJ, et al: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250:1262-1266, 1990
39. Mineta T, Rabkin SD, Yazaki T, et al: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938943, 1995
40. Meignier B, Martin B, Whitley RJ, et al: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162:313-321, 1990
41. Markert JM, Medlock MD, Rabkin SD, et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7:867-874, 2000
42. Rampling R, Cruickshank G, Papanastassiou V, et al: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7:859-866, 2000
43. Advani SJ, Mezhir JJ, Roizman B, et al: ReVOLT: Radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66:637-646, 2006
44. Advani SJ, Sibley GS, Song PY, et al: Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther 5:160-165, 1998
45. Kemeny N, Brown K, Covey A, et al: Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17:1214-1224, 2006
46. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376, 1996
47. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000
48. Nemunaitis J, Ganly I, Khuri F, et al: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 60:6359-6366, 2000
49. Nemunaitis J, Khuri F, Ganly I, et al: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289-298, 2001
50. Rodriguez R, Schuur ER, Lim HY, et al: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57:2559-2563, 1997
51. Chen Y, DeWeese T, Dilley J, et al: CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 61:5453-5460, 2001
52. Collis SJ, Khater K, DeWeese TL: Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol 21:275-289, 2003